Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells 5,455 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 5,455 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $9.14, for a total transaction of $49,858.70. Following the completion of the sale, the chief operating officer owned 383,837 shares of the company’s stock, valued at approximately $3,508,270.18. The trade was a 1.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The shares were sold at an average price of $8.54, for a total transaction of $51,538.90.

Ocular Therapeutix Stock Up 0.5%

Shares of NASDAQ OCUL traded up $0.04 during mid-day trading on Wednesday, reaching $8.55. The company had a trading volume of 6,694,837 shares, compared to its average volume of 5,361,677. The stock has a market capitalization of $1.82 billion, a PE ratio of -5.94 and a beta of 0.90. Ocular Therapeutix, Inc. has a twelve month low of $5.78 and a twelve month high of $16.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.78 and a current ratio of 7.85. The stock’s 50 day moving average is $11.94 and its 200-day moving average is $11.97.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%.The firm had revenue of $14.54 million for the quarter, compared to the consensus estimate of $14.57 million. As a group, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OCUL has been the topic of a number of research reports. TD Cowen restated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Needham & Company LLC reissued a “buy” rating and issued a $20.00 target price on shares of Ocular Therapeutix in a research report on Monday, December 8th. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 9th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus target price of $22.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 893 shares during the last quarter. KBC Group NV bought a new position in shares of Ocular Therapeutix in the fourth quarter worth about $78,000. Quarry LP acquired a new position in shares of Ocular Therapeutix during the third quarter worth approximately $80,000. Finally, Trust Co. of Vermont increased its position in Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,750 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.